We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial
News

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial
News

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that it has received a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial with a novel HuCAL antibody. The antibody will be tested in the field of cancer. Financial details were not disclosed.

"This is the 13th therapeutic antibody based on MorphoSys's technologies that Novartis is evaluating in clinical trials, thus making our collaboration one of the most successful antibody alliances in our industry" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

"During the course of this year, the MorphoSys pipeline has further matured and currently includes more programs in clinical trials than ever before. This reflects the great value of both MorphoSys's technology and the resulting products, in our partnered as well as proprietary pipeline."

MorphoSys's clinical pipeline now comprises 28 clinical programs. Two of them are in phase 3, 15 in phase 2 and 11 in phase 1. Novartis has currently 13 HuCAL antibodies in clinical development, of which six are in phase 2 and seven in phase 1.

Advertisement